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Molecular definition of disease at the level of the gene 
and advances in recombinant DNA technology suggest 
that many diseases are amenable to correction by genes 
not bearing the defective elements that result in dis­
ease. Many questions must be answered before this 
therapy can be used to correct chronic diseases. These 
questions fall into safety and efficacy categories. Expe­
rience with transplanting cellular elements of skin or 
skin substitutes (defined as skin that possess the cell 
types and a dermal structure to develop into a func­
tioning skin) to athymic rodents is considerable and is 
seen as a system where these questions can be answered. 
This paper reviews these questions and presents our 
early analysis of genetically modified cells in skin sub­
stitutes in vivo and in vitro. 
Experimental data demonstrate that both a matrix 
of woven nylon, housing a fibroblast generated col­
lage, and dead dermis can be utilized to shuttle geneti­
cally modified human fibroblasts from the laboratory 
to an in vivo setting. Genetically modified fibroblasts 
do not migrate from the shuttle to the surrounding 
W ithout resorting to hyperbole it can be stated that the status of h:alth or dise�e inh�ren� to an organ or orgamsm at any given time IS a result of the regulation of genes and their products. When this regulation is abnormal 
there are consequences that have patterns that physicians have 
learned to recognize as specific diseases. This is true whether the 
abnormality is via inheritance of an abnormal gene, infection with a 
microorganism, immune recognition of self, or mutational events 
that occur after birth. 
Recent knowledge and methods from the field of recombinant 
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tissue. The survival of significant numbers, - 70%, of 
genetically modified fibroblasts for at least 6 weeks in 
these shuttles, supports this general approach as having 
clinical utility. It is also concluded that skin substitute 
systems can be used to generate a genetically modified 
skin in fIitro that has the capacity to develop into func­
tional skin in vivo. Further, as genetically modified 
keratinocytes differentiate there is increased produc­
tion by the transgene, supporting the concept that ker­
atinocytes have true potential as shuttles for therapeu­
tic genes. 
This work demonstrates that transplantation of sys­
tems containing genetically modified cells of the skin 
can be used to experimentally define many aspects of 
gene therapy using skin before this technology is taken 
to the clinic. Examples include determining the effect 
of gene transduction and expression on structure and 
function of the genetically modified skin as well as on 
distant skin and an assessment of the translational ca­
pacity of the transgene as function of time and cell 
number.] Invest Dermatol10J:76S-84S, 1994 
DNA technology have made it increasingly possible to define 
health as well as disease at the level of the gene. This technology has 
generated molecular tools for mapping genes to specific locations 
on the chromosome, for nucleotide sequencing of normal and dis­
eased genes, and for constructing plasmids that produce genes and 
their gene products in vitro. Over the past 10 years, application of 
this technology has also generated, at an ever increasing pace, spe­
cific genetic and molecular tests for disease, a molecular basis for 
physiology and pathology in health and disease as well as a rational 
basis for therapy. With these tools and the knowledge generated 
came the realization that corrected copies of defective or deleted 
genes might be placed in cells of patients to treat specific afflictions, 
i.e., gene therapy. This exciting possibility became reality in 1990 
when the gene carrying adenosine deaminase was introduced into 
lymphocytes of patients suffering from severe combined immuno­
defiCj.ency of childhood and the infusion of these genetically modi­
fi� '(GM) cells back into the patient [1]. 
This success has led to an explosion of gene therapy protocols for 
human subjects (43 approved by NIH and FDA approval boards by 
May of 1993) for a growing list of diseases. A partial list includes: 
placing the gene for CFTR (cystic fibrosis transmembrane conduct­
ance regulator) in the respiratory epithelium of patients afflicted 
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with cystic fibrosis; adding the gene for TNF-a to tumor infiltrat­
ing lymphocytes prior their expansion in vitro and injection back 
into cancer patients to augment tumor killing and placing genes in 
tumor cells to make them more immunogenic [2]. 
GENE THERAPY VIA SKIN/POTENTIAL 
It has been obvious that skin should be an ideal organ for gene 
therapy, for some of the reasons listed below. 
• Cells of the skin are readily obtained, cultured, cryopreserved, 
and passaged; making it possible to use autologous cells for ge-
netic modification. . 
• A num�er of genes have been successfully transduced into c�Hs of 
the skin; growth hormone [3], humanfl-chorionic gonadotropin 
[4], lacZ (see below) [5], factor VIII and IX [6,7,8], chloramphen­
icol acetyltransferase (CAT) [9], human insulin [10], human 
transferrin (unpublished observations Kaplan], Morgan]R, Uni­
versity of Utah and Shriners Bum Institute, 1993), a 1-antitryp­
sin [11], human adenosine deaminase [12] and granulocyte­
colony simulating factor [13]. 
• Systems for shuttling genetically modified (GM) fibroblasts and 
or keratinocytes from the laboratory to the patients are available 
and have undergone some clinical testing, see below. 
• Symptoms of a mucopolysaccharide storage disorder in mice 
(MPS VII), analogous to human disease, have recently been 
corrected by transducing the human fl-glucuronidase gene into 
MPS VII fibroblasts that were placed into a shuttle of collagen 
coated polytetra-fluoroethylene fibers (Teflon) and transplanted 
intraperitoneall y [14]. 
• Procedures for the clinical transplantation of skin substitutes, (ep­
idermis, split-thickness grafts, etc.) are routine. 
• Skin is easy to examine for possible unwanted effects of gene 
therapy on the structure and function of skin 
• If unwanted events occur in the GM skin, it can be removed. 
• Blood supply to skin exceeds metabolic needs by -1 OX. This 
feature should enhance the transport of therapeutic gene products 
from skin to the systemic circulation [15]. 
This paper focuses on the practical aspects of the potential, as well 
as the limitations, for correcting disease states using GM cells of the 
skin. Many important elements of gene therapy are not addressed, 
e.g., the disease or pathologic events of interest needs to be defined 
at the level of the gene; the gene of interest needs to be suited for 
replication in recombinant form in vitro; techniques are needed for 
placing the gene of interest into the cells that are to be transported to 
the patient; and methods are needed for promoting and controlling 
the gene transferred (trans gene). The bibliography includes selected 
reviews of these important issues [1,16-21]. 
The major question is what types of disorders can be corrected by 
placing genes in cells of the skin? At least three general types of 
disorders appear amenable to gene therapy using cells of the skin. 
The first is correcting systemic disorders with GM skin cells. 
Prototype diseases might be ones characterized by an abnormality in 
'01 plasma protein, such as hemophilia due to either factor VIII or IX 
deficiency [21] or a 1-antitrypsin deficiency associated with em­
physema [11]. Other examples could be the impaired immune states 
inherent to diseases such as leprosy, tuberculosis, and AIDS. Here 
vectors that allow the selective over-production of a cytokine such 
as IFN-l' could be placed in cells of the skin to upregulate the more 
protective T HI response and to downregulate cytokines that drive 
TH2 type responses, the latter being non-protective to the host in 
these diseases [22]. For these types of disorders the gene product 
would necessarily need to be transported from the site of generation 
in the skin to sites expressing disease. This aspect is covered in 
further detail in sections to follow. 
The second group are skin disorders that are localized. At least 
two types of localized skin disease are potential targets; those caused 
by genetic defects and those that are autoimmune in nature. Candi­
date diseases in the former are: those with a defined gene defect, 
those where expression occurs later in life, those with localized areas 
of expression, and those where the heterozygous carriers are asymp-
GENETICALLY MODIFIED SKIN TO TREAT DISEASE 77S 
tomatic (i.e., one half or less of levels of a gene product will correct 
disease to the level of the asymptomatic cartier). In these diseases a 
corrected copy of the gene inserted into the element of skin (kerati­
nocyte, fibroblast, melanocyte, etc.) most responsible for disease 
expression should result in a normalization of the disease. Because 
Darier's disease (keratosis follicularis) is inherited, presents late in 
childhood and frequently remains localized in expression, it is a 
candidate disease. Once the gene defect is delineated, placing a 
corrected copy of the gene into cells of the affected areas could do 
much to moderate disease. Other candidate skin diseases that have 
been or are in the process of being genetically defined, that are 
localized in expression, and that cause most of their morbidity later 
in life include several forms of epidermolysis bullosa, the basal cell 
nevus syndrome, and ultra-violet light induced squamous and basal 
cell carcinomas caused by mutations in p53 or other tumor genes 
[23,24]. Inherent to these considerations is whether such genetic 
diseases have to be corrected locally or can be corrected by genes at a 
remote site. 
Correction of localized expression of autoimmune disease might 
be accomplished by several approaches. Examples include supplying 
a gene that alters trafficking of inflammatory cells, supplying a gene 
that upregulates suppression or downregulates antigen recognition 
moieties such as B7, or supplying a gene whose products (IL-4, IL-5, 
and IL-I0 versus IL-2 and IFN-y) respectively facilitate switching 
cells from T H2 (non-opsonizing antibody phenotype production 
IgA, & IgE) to THI (cell mediated and opsonizing 19 phenotype) 
phenotype [17,22]. Diseases approachable with these types of gene 
therapy include dermatitis herpetiformis, psoriasis, atopic dermati­
tis, localized scleroderma, and discoid lupus erythematosus. 
The third group represent a broader perspective, correcting gen­
eralized skin disorders, either auto immune (e.g., generalized scle­
roderma) or genetic (e.g., epidermolytic hyperkeratosis, lamellar 
ichthyosis, or mucopolysaccharide storage disorders) with gene 
therapy using cells of the skin. The principles are the same, however 
the candidate gene or its product needs to be delivered from local­
ized sites to the entire skin and to other organs if more than the skin 
is affected. These localized sites could carry and express the normal 
gene or house genes that can regulate expression of genes that give 
rise to disease, e.g., autoimmune processes. 
GENE THERAPY VIA SKIN/LIMITATIONS 
For each of the forgoing examples using genetically altered skin to 
correct disease, there are a series of questions that serve to define the 
limitations of this promising form of therapy. 
Which Cell(s) Should Be Used to Shuttle the Therapeutic 
Gene to the Skin? If the defect is localized, and selectively ex­
pressed by elements in the skin, e.g., epidermis, it is intuitive that 
the gene be placed in keratinocytes. Because the epidermis does not 
have an active blood supply, expression of the trans gene in the 
dermis seems most appropriate where transport to systemic circula­
tion is required. However, this may be only theoretical. Recently 
Fenjves et ai, in association with our group, have shown that human 
apolipoprotein-E made by keratinocytes is present in the sera of 
nude rats bearing human skin grafts on the rat sandwich flap system 
[25]. Higher levels were noted in blood draining the flap bearing the 
grafts than in the systemic circulation, (13.8 ± 0.2 ng/mI versus 
8.8 ± 0.3 ng/mI, respectively). Thus, the lack of an active blood 
supply is less of a concern. In actuality no cell has a direct blood 
supply, all having at least a cell membrane and/or other matrix 
elements between the site of production and blood. 
Are There Limitations in the Number of Cells That can be 
Made to Express the Transgene in a Given Tissue? It is plau­
sible that if every cell carties one or more copies of the trans gene an 
alteration in structure and function of skin could develop. Studies of 
over-production of factors normally made by cells of the skin have 
been and are being conducted in transgenic mice. Some have caused 
substantive changes, (e.g., over-expression ofTGF-flt causes a taut 
skin with an increased stratum corneum and diminished number of 
hair follicles in affected pups) [26]. The number of genetically al-
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tered cells needed to produce this effect is unknown. For every cell 
to carry the trans gene, cells have to be cloned after transduction or 
transduction has to be at 100% efficiency. 
Will the Product of the Traasgene be Immunogenic or In­
duce an Immune R.esponse to the GM Cells? It is presumed 
that a gene product that is endogenous to the healthy counterpart 
will not be immunogenic when expressed in patients. However, 
there is evidence to indicate that human factor IX made by GM 
murine fibroblasts can be immunogenic when transplanted to syn­
geneic mice [5]. 
What are the Limits of Production by the Transgene in GM 
Skin, i.e., Is There a Dose Response and Does the Gene Prod­
uct Have a Shortened Half-Life' A recent report notes that 
human factor VIII has a much abbreviated half-life in mice bearing 
GM murine fibroblasts [6]. 
Is the Transgene Stable. Does it Become Inactivated as a 
Function of Time. Does the Cell Bearing the Transgene Be­
come Senescent. Is the Cell Bearing the Transgene R.ejected 
[5,12.16.18]' 
Will the Genetic Alteration Activate Proto-Oncogenes and 
Cause Tumors to Form, Will the Traasgene Alter Homeosta­
sis Su8icient to Cause Abnormal Structure, and/or Function 
in Skin Carrying the Genetic Modification? There are no 
known reports of this occurring. 
Is the Transgene Product Intended to Have Autocrine. Para­
crine. or Endocrine EfFects, i.e. will the Gene Product Leave 
the Site of Origin, The answer will govern the cell type used. 
What are the Most Clinically Relevant Methods for Generat­
ing GM Skin? It is �ppreci�ted that need directs ch?ice, the broad 
choices are 1) a matr1X carrylng GM fibroblasts burled subcutane­
ously to deliver gene products to the systemic circulation or placed 
intradermally for delivery to the surrounding dermis or overlying 
epidermis; 2) a skin substitute, defined as a matrix carrying normal 
or GM fibroblasts with the potential for developing an epidermis 
from normal or GM keratinocytes seeded on the surface; 3) GM 
keratinocytes to replace an epidermis that has been removed. The 
concerns are how to remove the existing epidermis, when and how 
to replace it with the GM elements, and whether follicular kerati­
nocytes of the host will gradually replace the GM element. 
There are a number of dermal matrices that are readily impregnated 
with fibroblasts that can also be seeded with keratinocytes: 1) a 
nylon matrix dermal model (see below) implanted with fibroblasts 
that generate collagen that fills the matrix and surrounds the nylon 
fibers. (Advanced Tissue Sciences, La Jolla, CA) [27 -:-29]; 2) a dead 
dermis (DeDD, see below) generated from human skin pO.31]; .3) a 
collagen gel to which fibroblasts are added de novo or In combina­
tion with a support structure such as polytetra-fluoroethylene fibers 
(Teflon) [14.28.32 - 34); 4). a mesh genera�e� from polyglycolic 
acid (Vicryl) impregnated wlth fibroblasts (LlVlng Dermagraft. A�­
vanced Tissue Sciences. La Jolla. CA); and 5) a collagen-glycosanu­
noglycan dermal substrate with or without a laminated sheet of 
collagen on one surface for attachment of keratinocytes [35 - 37]. 
The first two do not undergo biodegradation in the short term 
(unpublished observations of transplants to nude mice for more than 
two months); the other three have potential to biodegrade. There 
are no studies that compare biodegradability of a shuttle with its 
efficacy to move GM cells to an in vivo setting. 
Are Stem Cells Needed? Short term (weeks to months) survival 
of primary GM fibroblasts has been dem�nstrated in several in vivo 
settings [5,12-14,16]. There are no studies that show that th� GM 
cells persist for the life of the host. It is accepted that pnmary 
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cultures of keratinocytes and fibroblasts undergo senescence in vitro. 
It is presumed that this also occurs in vivo. Thus, the time that a cell 
carrying a transgene in its genomic DNA would be therapeutic is 
proportional to the number of progeny and the life span of each. In 
the absence of active shut-down by host tissue, the length of time 
that a transgene or its message is operational after cell division ceases 
is unknown. Because skin survives despite age-associated senescence 
in vivo, it is accepted that stem cells (cells possessing unlimited 
renewal capacity) exist in skin. Placing the transgene in the genomic 
DNA of a stem cell would hypothetically circumvent this potential 
cause of loss of therapeutic effect. However, to date, the source and 
nature of stem cells in skin have not been identified for human skin. 
It should be noted that predicted shut-down could be used in se­
lected settings, e.g., situations requiring short-term gene therapy, 
such as treatment of an acute illness. 
Proliferative events will predominate over differentiative events 
for some time after implanting GM tissue. With differentiation the 
typical cell shifts to the manufacture of products that lead to its 
function. Thus, unless regulatory elements in the vector dictate 
otherwise, it is predicted that GM cells will produce more gene 
product as proliferation returns to baseline and differentiation be­
comes dominant. This hypothesis is supported by the observations 
that keratinocytes express more of the trans gene ( CAT) with differ­
entiation [9]. Whether these biologic observations and conjectures 
are uniformly operative and in harmony with the promotors used 
with the trans genes and with the concept of random insertion of the 
transgene into host genomic DNA is to be determined. 
What is the Best Method to Deliver the Selected Genel Sev­
eral methods have been used to introduce genes into cells and or 
hosts [16,18,20,38-40]. 1) One method is physico-chemical, e.g., 
CaP04, DEAE-dextran, liposomes, etc. 2) Another is micro injec­
tion into cells or tissue, e.g., muscle. 3) There is electroporation or 
Gene Gun (DNA-coated gold beads). 4) In ligand directed delivery, 
DNA (trans gene) is attached to a ligand and delivered to cells via the 
receptor for the ligand. This model suggests it is possible to trans­
port a transgene attached to a ligand via the bloodstream to a specific 
tissue with tissue specific receptors or modified to express binding 
sites for the ligand. Work by W u and W u [41], using a binding site 
for asialoglycoprotein, demonstrates feasibility for using this tech­
nique to deliver transgenes to the liver. Another example might be 
the induction of over-expression of class II MHC antigen in the 
epidermis with INF-y, conjugating the transgene to an antibody for 
the specific MHC antigen and injecting it intravenously. 5) In viral 
directed delivery, viruses are used because of their selective ability to 
enter cells. Types of viruses under consideration include the retrovi­
rus, adenovirus, adeno-associated virus, herpes virus, HIY. and pa­
povavirus. For reasons listed in the following paragraph the major­
ity of exr.erience in gene transfer has been with retroviruses 
[16,18,20. 
The first three transduction methods on this list are generally 
quite inefficient, < 1 % of cells being successfully transduced. This 
contrasts with transduction with retrovirus technology where 
transduction efficiencies > 20% are common. Additional advan­
tages of retroviruses for gene transduction include 1) they have 
amphotropic host range. i.e .• will infect � variety of cellsr inclu�g 
huq.tan; 2) stocks of recombinant retrovlrUSes that are free of wlld­
type replication-competent virus can be produced from specialized 
packaging cell lines; 3) their integration into host genomic DNA is 
efficient and provides a stable provirus with predictable structure. 
Transduction with adenovirus is also very efficient as large num­
bers of cells can be made to carry multiple copies of the transgene 
[18]. However, the transgene is episomal (i.e .• it does not incorpo­
rate into host genomic DNA) and hence will have a limited life 
span. 
Can GM Cells of the Skin Be Used to Correct a Relevant 
Disorder in a Rodent Model? There is at least one rodent 
model of disease where gene therapy has been used. In the mouse 
model of an inherited mucopolysaccharide storage disorder (MPS 
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Table I. Predicted Production of Gene Product by Cells of Skin 
Type of GM Tissue Tissue Volume pm' X 1010 Number of Cells X 107 Production in ngjh 
Skin equivalent with GM keratinocytes & GM fibroblasts 
Graft on rat flap (2 X 3 em X 150 pm) 
Graft on mouse (2 X 2 em X 150 pm) 
Skin with GM epidermis 
On rat flap (2 X 3 em X 150 pm) 
On mouse (2 X 2 em X 150 pm) 
Skin with GM dermis 
Implant (2 X 2 em X 500 pm) 
Implant (2 X 2 em X 1000 pm) 
VII) many symptoms were corrected by transplanting fibroblasts 
bearing the human p-glucuronidase gene to affected mice [14]. 
PREDICTED PRODUCTION BY GM SKIN 
Factors affecting the potential for correcting genetic or acquired 
disorders with GM skin are 1 )  the number of GM cells, 2) the 
inherent production rate by the transgene, 3) degradation and/or 
elimination of gene product(s), 4) presence of receptors for the gene 
product,S) solubility of the gene product in the tissue within which 
it is generated in, 6) blood flow to this tissue, and 7) solubility in 
blood. We have calculated the number of GM keratinocytes (GMK) 
or GM fibroblasts (GMK) that can be carried in the various types of 
grafts that can be transplanted to athymic rodents. These are the 
number of GMD contained in a GM epidermis that would replace 
the existing epidermis of an orthotopically engrafted human split­
thickness skin graft; the number of GMF carried in an artificial 
dermal matrix that would be placed in the subcutaneous tissue; and 
the number of GMK in the epidermis and the GMF in the dermis of 
a skin substitute. From this we have calculated the potential rate of 
production by these GM tissues using currently available promoters 
(see Table I). These calculations support the contention that some, 
perhaps many, heritable disorders can be corrected with GM skin. 
These calculations assume the following: 1) Kc are approximately 
1000 pm3 in volume, 1 0  p.m on a side [15] and give rise to the 
epidermis which is -50 p.m thick; 2) The number of fibroblasts in a 
dermal matrix, - 300 p.m thick, is equivalent to the number of 
keratinocytes in a like area of the overlying epidermis; 3) In a human 
skin graft on the rat human skin sandwich flap, the epidermis can 
easily measure 2 em X 3 cm X 1 50 p.m in thickness, a volume of 
9 X 1010 pm3• An orthotopic human skin graft on a mouse typically 
can measure 2 em X 2 em in diameter X 150 pm in thickness, 
4.7 X 1010 pm3 [42]; 4) In orthotopically grafted skin that is re-epi­
thelialized with GMK, the productive epidermal volume is 3 X 
1010 pm3 and 1 .57 X 1010 p.m3 for the rat flap and the mouse graft, 
respectively; 5) a dermal matrix 1 mm in thickness and 4 X 4 em in 
size has a volume of 1 .6 X 1012 p.m3; 6) the number of GM cells in 
each of the combinations equals volume of tissue/volume of cells 
(aU cells are assumed to be 1 ,000 p.ml, an overestimate of the size of 
fibroblasts and extracellular space is ignored; 7) expansion of tissue 
or death of cells during and after engraftment likely will occur, this 
has not been included in these estimates; 8) with current retroviral 
vectors the rate of production by the transgene of GM cells is - 5-
20 ng/l06 cells/h, this presumes all cells carry the gene (Jeff Mor­
gan, personal communication, 1993); 9) production equals number 
ofceUs X the rate X time; 1 0) blood levels can be predicted with the 
formula P = 
In2 
X (X), where P, the production rate in ng/h; X, 
r.. 
the level of protein in the blood, in ng/ml, X the total plasma 
volume; average 70 kg man, 2700 ml; In2, the natural log of 2; tt, 
the half life of the protein in hours. 
This analysis suggests that the range for GM skin to correct dis­
ease is considerable. These estimates and the progress noted in the 
forgoing sections make it probable that a new field of pharmacology 
will emerge, the pharmacology of genes and gene products, it will 
encompass parameters that define production, (e .g . ,  promotors, 
9 9 450-1800 
4.7 4.7 235-940 
3 3 3150-600 
1.6 1.6 164-256 
20 20 1000-4000 
160 160 8000-32000 
number of gene copies per cell , etc); parameters that define transport 
in tissue, size, charge, solubility, etc; solubility in tissue and blood; 
pharmacokinetics of gene products in situ, t! in tissue versus blood; 
and pharmacodynamics, dose/response. 
PROGRESS TOWARD USE OF GENETICALLY 
MODIFIED (GM) CELLS OF THE SKIN TO CORRECT 
DISEASE 
Recently we initiated work that is directed at determining the feasi­
bility of using GM cells of human skin to correct disease by analyz­
ing the GM elements in vitro and in vivo after transplantation to 
athymic rodents . There are three long term objectives. First, deter­
mine the long-term functionality of skin containing GM compo­
nents in an in vivo setting, (specifically, the stability of the trans gene 
and production of its product, the aspects that define a dose response 
and the effect of the trans gene on structure and function inherent to 
skin). Second, develop the necessary technology for transplanting 
GM skin to humans using transplantation of GM skin to athymic 
rodents as a developmental intermediary, (specifically, an approach 
to replace the existing epidermis with an epidermis generated from 
GM keratinocytes and generating a GM skin-equivalent that carries 
normal or GM fibroblasts or keratinocytes that can be transplanted 
onto athymic rodents). Third, determine whether disease can be 
corrected with keratinocytes and or fibroblasts transduced with the 
appropriate gene. The remainder of this manuscript reports relevant 
aspects of progress on the first objective. 
MATERIALS AND METHODS 
The athymic (nude) mice supplied by Charles River, Wilmington, MA., 
used in these experiments were BALB/c, male, and - 3 months of age at the 
time of grafting. 
Two dermal substrates to shuttle GM cells to nude mice have been used in 
these studies. The first is the living dermal model (LDM) supplied by Ad­
vanced Tissue Sciences, La Jolla, CA. This substrate is a nylon mesh that is 
treated to promote fibroblast adhesion, seeded with foreskin fibroblasts at 
Advanced Tissue Sciences, held under tissue culture conditions for three 
weeks and incubated with media selective for fibroblasts supplemented with 
ascorbic acid. During this time the interstices of the mesh fill with fibroblasts 
and collagen. Thereafter the LDM is cut into 1.3 em X 1.3 em squares, 
subjected to hypotonic lysis (HLDM) to kill the fibroblasts and shipped to 
our laboratory where it is stored at-70'C in DMEM with 10% fetal bovine 
serum (FBS). 
The second dermal substrate is dead dermis (DeDD) that is generated 
from human skin using a procedure modified from Langdon and McGuire 
[30] . Within 4 h of surgery remnant skin from elective abdominoplasties is 
delivered to our lab in containers filled with saline supplemented with 
antibiotics and a fungicide. It is keratomed to 500 pm thickness with a 
Padgett Electro Dermatome, Kansas City, MO., placed in a 56 to 60·C 
water bath for 30 seconds and the epidermis peeled away with forceps. The 
DeDD is subjected to 3 freeze (-70· C) thaw (24· C) cycles at 24 h intervals, 
irradiated with a cesium source (5000 cGy), cut into 1.5 em X 1.5 em pieces 
and stored at -70'C. 
Histologic analyses of the HLDM and the DeDD demonstrate nuclear 
debris without evidence of viable cells. This is supported by finding no cells 
on tissue culture plates housing the HLDM or the DeDD when held under 
tissue culture conditions (DMEM with 10% FBS and 10% CO2 at 37'C) for 
prolonged periods, more than 30 d. 
Cell types used in these experiments include a NIH 3T3 cell line, three 
different human fibroblast sources, neonatal (two), generated from fore· 
80S KRUEGER ET AL 
skins, abbreviated FsF and adult (one), generated from abdominoplasty skin, 
abbreviated AdF. To establish these fibroblast cultures the skin was disso­
ciated with trypsin, fibroblasts collected and seeded at relatively high den­
sity, grown to confluence, harvested, expanded, and passed X 3, frozen, and 
stored in liquid nitrogen. After expansion the 3T3 line was stored in liquid 
nitrogen. 
In skin substitute experiments the dermal substrates were seeded with 
neonatal fibroblasts (1 X 106) at day 0 and held in culture for 14 d; on day 15 
neonatal keratinocytes [1 X 106/50 pI of KGM (keratinocyte growth 
media), Clonetics, San Diego, CAl were seeded on the surface. On day 16 
these skin substitutes were transplanted to the subcutaneous space of the 
lateral thoracic cage of nude mice. Wounds were closed with wound clips, 
which were removed 10 -14 d later. Grafts were excised at periodic intervals 
for histologic assessment. 
Two retroviral vectors encoding the gene for lacZ from Escherichi coli and 
the gene for humanp-chorionic gonadotropin (p-hCG) have been used. The 
former is termed a-SCG-lacZ and houses the promoter from CMV for 
a-globin. It is used with the permission of Somatix Therapy Corporation, 
Alameda, CA [43]. The latter is a retrovirus encoding the p-subunit of 
human chorionic gonadotropin. This vector, termed KSG p-hCG, has a 
promoter fragment and upstream sequences from a pseudogene of K14, a 
50-KDa keratin protein expressed at high levels in keratinocytes and an 
efficient packaging sequence that increases the frequency of transduction of 
keratinocytes [4]. These vectors have been transfected into the 3T3 packag­
ing cell line IfI-CRIP [44]. The 3T3 transfected lacZ cell line (3T3.T.lacZ 
producer) was expanded, tested for viral titer, frozen, and stored in liquid 
nitrogen. The 3T3 p-hCG producer was used to transduce foreskin kerati­
nocytes shipped to Utah, expanded, and seeded (at 8 X 10s/cm2) on a fi­
broblast impregnated collagen-glycosaminoglycan dermal substrate with a 
laminated sheet of collagen on one surface for attachment of keratinocytes 
[36]. Culture conditions, a 60: 40 mix ofKGM and DMEM with 10% FBS 
[45], supported fibroblast growth as well as keratinocyte proliferation and 
differentiation. Every 72 h spent media was collected, p-hCG measured by 
ELISA, and new media added: 
The supematent from the 3T3.T .lacZ producer line was used to transduce 
3T3 cells and fibroblasts from human sources. Transduction with virus 
carrying lacZ followed the format of splitting the cells to be infected on day 
0, passing them at passage density, at day 1 adding undiluted fresh or thawed 
lacZ virus from the producer line with polybrene (4 pg/ml) and returning 
cells to the incubator with gentle shaking every 30 min. After 2 h media was 
withdrawn, new media added, and cells returned to the incubator at 37°C 
and 10% CO2, When cells reached confluence, 3-5 d later, media was 
removed, plates fixed with 0.5% glutaraldehyde in PBS for 10 min at room 
temperature, and stained for lacZ with X-gal. LacZ remains in the cyto­
plasm; cells expressing lacZ stain blue after incubation with the substrate, 
5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-gal) [46]. The efficiency 
of transduction is measured by staining for lacZ using X-gal and estimating 
the fraction of positive cells microscopically. For the 3T3 cells this ranged 
from 50-60%. for adult fibroblasts from 1-25% and for neonatal fibroblasts 
from 10-40%. 
The lacZ transduced cells (3T3, adult fibroblasts, neonatal fibroblasts) 
were expanded by growing to confluence, harvesting, splitting, and 
passage X 3. One million of the lacZ transduced cells were added to the 
upper surface of freshly thawed squares of HLDM or DeDD in a volume of 
media that did not let fluid spill over the edge of the HLDM (- 50 pI). These 
combinations were held in vitro for up to 28 d or were transplanted to the 
subcutaneous space of the lateral thoracic cage of nude mice at day 8. 
Wounds were closed with wound clips. Transplants were removed at 2 week 
intervals for 6 weeks and analyzed for lacZ expression using the X-gal 
staining procedure [46]. The HLDM requires plastic embedding and 5 pm 
sections for optirnal histologic assessment. Staining whole tissue with X-gal 
results in surface staining only, thus tissue needs to be trimmed to a 1 to 
2 mm thickness before staining for lacZ. The X-gal stain survives the tissue 
sectioning process. Sections were counter-stained with hematoxylin and the 
number of positive cells estimated on a 0 to 4 scale where 0 = none and 
4 = all cells as positive for LacZ. The procedure for the DeDD was the same 
only it was submitted for routine tissue sectioning. 
The need to know the fate and effect of GM cells in or on these substrates 
when all cells carry the trans gene caused us to clone GMF, using the limiting 
dilution technique. This cloning utilized the neonatal foreskin fibroblast 
source that was most efficiently transduced with the viral supernatent carry­
ing lacZ. Two clones emerged. one did not passage and one did. It was placed 
on the HLDM as noted above and handled in a manner analogous to the 
non-cloned component. 
RESULTS 
Transplant of Dermal Substrates Seeded with Keratinocytes 
and Fibroblasts to Nude Mice It was conjectured that a shuttle 
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Figure 1. Representative photomicrographs (A, bar = 100 pm) and 
(B, bar = 50 Jlm.) of a dead dermis (DeDD) 6 weeks after transplanta­
tion to the subcutaneous space of athymic (nude) mice. Prior to trans­
plantation the DeDD was seeded in vitro with human fibroblasts at day O. At 
day 15 human keratinocytes were added to the surface and the resultant skin 
substitute transplanted on day 16. Note the density of fibroblasts and the 
normal appearance of the epidermis. 
system to carry GM cells to the patient needs to have a demonstrated 
capacity to house the basic elements for a skin substitute (epidermis 
and dermis) in vitro and the potential to evolve into a functional 
epidermis and dermis in vivo. Thus an initial objective was to dem­
onstrate that the dermal substrates, the dead dermis (DeDD), and 
the hypotonically-lysed dermal model (HLDM), could be seeded 
with keratinocytes and fibroblasts and transplanted to nude mice to 
evolve into a skin substitute (defined as skin containing a defined 
source of keratinocytes, fibroblasts, and dermal matrix that has the 
potential to function as normal skin). 
Histologic analysis of DeDD grafts, seeded with keratinocytes 
and fibroblasts, at days 14, 26, and 35 demonstrated five of eight 
grafts with an intact epidermis and fibroblasts throughout the 
DeDD, (Fig 1). Analysis of the HLDM revealed an immature epi­
dermis overlying a fibroblast impregnated matrix (Fig 2). When 
left ait exposed the HLDM skin quickly desiccates and becomes 
nonviable. No inflammatory nor foreign body response was noted 
in tissue surrounding either skin substitute. Transplanting a fibrob­
last free HLDM demonstrated the density of mouse fibroblasts that 
move into this dermal substrate equals that of a LDM that was not 
lysed hypotonically and achieves the fibroblast density noted in the 
HLDM seeded with fibroblasts, noted in Fig 2. These features show 
that these systems have the potential to answer many of the ques­
tions associated with the technology of correcting diseases using 
GM keratinocytes and or fibroblasts. 
Genetically Modified 3T3 Cells Seeded Unto Dermal Ma. 
trices 3T3.T.lacZ seeded onto a HLDM demonstrated that there 
was sufficient migration into the collagen by day 8 to permit subcu-
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Figure 2. A representative photomicrograph (bar, 100 Jim) of a hy­
potonically-lysed living dermal equivalent (HLDM) 6 weeks after 
transplantation to the subcutaneous space of athymic (nude) mice. 
Prior to transplantation the HLDM was seeded in vitro with human fibro­
blasts at day O. At day 1 5  human keratinocytes were added to the surface and 
the resultant skin substitute transplanted on day 16 .  Note the density of 
fibroblasts and the immature appearing epidermis. 
taneous implantation. Holding them in vitro for additional time 
revealed increasing numbers of cells through day 20, with a decline 
thereafter. 
When transplanted to athymic mice, the 3T3.T.lacZ in HLDM 
developed into tumors. These were readily apparent by week 3,  and 
by week 8 were sufficiently large to cause us to sacrifice the animals. 
Grossly, these tumors stained positive for lacZ using the X-gal 
staining technique. A similar analysis was accomplished with 
3T3.T.lacZ seeded on DeDD. Migration of 3T3 cells into the 
DeDD did not occur. However, the cells did grow on the surface.  
Microscopic analysis of these tumors at 2,  6,  and 8 weeks demon­
strated many cells positive for the lacZ gene (Fig 3). However, the 
percent evidencing this gene product were fewer in vivo than in the 
early days in vitro. Reasons for this decrease include: the GM cells 
may be at some selective growth disadvantage relative to the non­
GM cells, there is mutational inactivation of the LacZ gene, or gene 
inactivation via methylation. Cloning by limiting dilution of 
3T3.T. lacZ reveals clones where all cells positive for lacZ before the 
cells reach confluence. At confluence it is common to find areas 
where lacZ is no longer expressed. This suggests that lacZ is some­
how inactivated at high density (confluence) in vitro. The in vivo 
corollary experiments have not been performed. 
The fact that 3T3 .T.lacZ gradually form tumors in and around 
these dermal substrates on nude mice is likely to be a useful tool for 
assessing gene product levels in blood vs. number of cells carrying 
the transgene as a function of time, i .e .  time - dose responses . 
Genetically Modified AdF and FsF to Dermal Matrices The 
analysis of lacZ survival in AdF transduced with lacZ and FsF trans­
duced with lacZ after seeding them onto HLDM or DeDD, holding 
them in vitro for 8 d and then transplanting them subcutaneously to 
athymic mice demonstrate 1 )  GM fibroblasts readily move into the 
HLDM; 2) GM fibroblasts surface seed onto DeDD and increase 
through day 1 6 ,  but do not move into the dermis; 3) in vivo, at days 
14, 18 ,  and 42, all three cell lines had gross and microscopic evi­
dence of lacZ in both the HLDM and DeDD. However, by day 42 
this was much more in evidence with the HLDM than with the 
DeDD; 4) the percent of cells demonstrating the lacZ gene is less in 
vivo than in the early stages in vitro; and 5) no inflammatory infiltrate 
is seen around either the HLDM or the DeDD implants bearing 
GM fibroblasts. 
Cloned Genetically Modified FsF to Dermal Matrices The 
apparent depletion of GM cells as a function of time caused us to 
A 
B 
GENETICALLY MODIFIED SKIN TO TREAT DISEASE 81S 
Figure 3. A low (bar, 300 Jim) and high-power (bar, 50 Jim) photomi­
crograph of a HLDM seeded with 3T3.T.lacZ, held in vitro for 8 d, 
grafted to athymic (nude) mice, and removed after various times of 
engraftment. These photomicrographs were taken of a tumor ( 1 . 5  cm X 
1 ,5 cm X 0.8 cm) of a 3T3.T.lacZ HLDM graft after 6 weeks of engraft­
ment. Only part of the tumor arising from the nylon matrix can be appre­
ciated at low power. The number of cells that are lacZ positive are marked 
with a (bullet) in the high-power photograph (blue staining lacZ positive 
cells cannot be distinguished in a black and white photo from background 
hematoxylin staining) . 
clone, via limiting dilution, a normal human neonatal fibroblast 
source transduced with lacZ. HLDM and DeDD were seeded as 
above with this clone and analyzed in vivo and in vitro . These experi­
ments demonstrate the following : 
1 .  It is possible to clone human fibroblasts that have been trans­
duced with a gene in a retroviral vector, expand same in vitro, and 
carry it to an in vivo setting with a dermal substrate.  
2. Cloned fibroblasts move into the internal aspects of the HLDM 
within 4 d, where they increase through day 8 (Fig 4); this 
contrasts with the surface where they continue to increase 
through day 21 before stabilizing . 
3. The density of GM fibroblasts within the collagen matrix of 
HLDM was that seen in non-hypotonically lysed HLDM in vitro 
and in HLDM placed in vivo without fibroblasts (see above) . 
4. All cells in the HLDM in vitro were positive for lacZ. 
5. Removal at days 14, 28, and 42 and staining with X-gal reveals 
most cells in the HLDM bear lacZ and that the DeDD also has 
many ce lls bearing lacZ (Fig 5) .  
6 .  By day 42,  versus day 1 4 ,  there i s  an - 30% reduction in the 
number of fibroblasts bearing the lacZ gene in the HLDM. It 
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Figure 4. Photomicrographs ofHLDM seeded with an expanded clone oflacZ-positive neonatal foreskin fibroblasts after 8 d in vitro (a, b) and 
after 42 d in vivo (c, d) . Cross sectional views (a, c) and en face views (b, d) are presented. NF and NF represent the crossing of the nylon fibers oEthe HLDM, 
(NF labels intersection in fibers , double fibers, NF labels the non-intersecting, single fiber, and no label is where the collagen has been laid down by human 
fibroblast between the nylon fibers before the LacZ fibroblasts were added. 1)  All of the dark staining cells are those expressing lacZ, 2) the interstices of the 
matrix are filled to capacity, 3) the lacZ cells are confined to the HDLM, 4) cells in mouse tissue (d) do not stain for lacZ and thus are not visible ,  5) the absence 
of an inflammatory infiltrate, or foreign body reaction. Size representation for Fig 4 (aJ through (dJ ; bar, 100 pm. 
appears that normal mouse fibroblasts move into the HLDM and 
replace or displace the cloned GM fibroblasts as a function of 
time (Fig 4). Whether this is because of senescence of the cloned 
GM fibroblasts or because the host fibroblasts are more aggres­
sive is unknown. 
7. In contrast with the experiment using 3T3 .T.lacZ cells , there is 
no expansion of fibroblasts into the surrounding subcutaneous 
tissue of the mouse with either shuttle system. 
8. No foreign body reaction is noted with either shuttle seeded 
with the cloned cells . 
These experiments demonstrate that both the DeDD and the 
HLDM can be utilized to shuttle GM fibroblasts from the labora­
tory to an in vivo setting and that the HLDM appears to be more 
efficient. The observation that the GM fibroblasts did not leave the 
constraints of the shuttle suggests that the GM cells (normal fibro­
blasts) stay where they are placed. The survival of significant num­
bers, - 70%, of GM fibroblasts for at least 6 weeks , demonstrates a 
clinical utility for transplanting a dermal matrix containing GM 
cells. Histologic analysis of a DeDD after it has been transplanted to 
the nude mouse for more than six weeks shows that it has a greater 
capacity for GM fibroblasts than the HLDM. The number of fibro­
blasts that can take up occupancy in the DeDD in vivo is approxi­
mately three times that of the HDLM. For this reason experimental 
approaches are being designed to enhance the number of GM cells 
that move into the DeDD before being transplanted. 
Production of p-hCG by Neonatal Keratinocytes In Vitro 
The ease of obtaining, culturing , and replacing keratinocytes from 
and on patients makes them attractive as a shuttle for therapeutic 
genes . A preliminary assessment of the po tential for production of a 
therapeutic gene by GM keratinocytes has been made using p-hCG 
transduced keratinocytes grown over a fibroblast impregnated der­
mal matrix, (see materials and methods) . Levels of p-hCG increased 
throughout the length of the 26 d experiment, (Fig 6) . Media was 
changed about every 3 d and P-h CG measured by ELISA. By defini­
tion, after each media change there is essentially no p-hCG in the 
media.  Nevertheless , with each media change , there was more 
product than at the previous media change , peak levels of 255 mili­
international units (miu} /ml being achieved by the last day (day 26) 
of the experiment . At day 26, the skin-equivalent was harvested and 
subjected to histologic assessment. This revealed that the epidermis 
was composed almost  totally of enucleated keratinocytes, i .e . , a thin 
stratum corneum. This supports the notion that with increased dif­
ferentiation there is increased production of transduced gene prod­
uct and supports the observation of increased expression of CAT in 
keratinocytes as a function of differentiation [9] . Production by 
differentiated cells is important to the feasibility of using GM kera­
tinocytes to treat disease as all keratinocytes have limited life spans . 
To avoid having to rep lace the GM cells at short intervals GM cells 
need to produce gene product in a differentiated state as long as 
possible . This potential problem could be overcome , in part, by 
transducing the gene into stem cells. 
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Figure 5. Low (a, "'r = 100 pm) and high-power (6, 6a1' = 50 pm) 
photomicrographs of DeDD seeded with a clone of lacZ-positive 
neonatal foreskin 6broblasts 42 d after subcutaneous engraftment to 
athymic mice, 1) LacZ cells, identified (by bullets) in b, are not unifonnly 
present in this substrate that has been counterstained with hematoxylin, 2) 
note the absence of an inflammatory infiltrate or foreign body reaction, 3) 
there is no tissue necrosis, 4) the density of fibroblasts is equivalent to that of 
a normal human dennis, 5) the space in this dermal substrate to hold GM 
fibroblasts is greater in the HLDM (see Fig 4). 
CONCLUSIONS 
These experiments demonstrate that both the HLDM and the 
DeDD can be utilized to shuttle GM fibroblasts from the laboratory 
to an in vivo setting. Importantly GM fibroblasts do not migrate 
from the structure to the surrounding tissue. The survival of signifi­
cant numbers of GM fibroblasts for at least 6 weeks in these shuttles, 
supports this general approach as having clinical utility. 
The increased production by the transgene with increased differ­
entiation and the observation that human apolipoprotein-E, made 
by keratinocytes, appears in the systemic circulation of animals 
bearing human skin grafts adds grist to the concept that keratino­
cytes have true potential as shuttles for therapeutic genes. The limi­
tations await in vivo assessment. 
It is also concluded that skin substitute systems will permit the 
generation of a GM skin in vitro and that they will go on to develop 
as functional skin in vivo after transplantation to the athymic rodent. 
With this we hope to gain answers to many of the questions that are 
central to understanding the ramifications of the potential as well as 
the limitations for correcting heritable diseases using GM keratino­
cytes and/or fibroblasts. 
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Figure 6, Production of p-bCG by human keratinocytes transduced 
with the '-bCG gene while being beld under ift "itro conditions for 
26 d. GM keratinocytes were seeded on a collagen-glycosaminoglycans der­
mal substrate seeded with human fibroblasts that were not subjected to 
genetic modification. Media was removed about every 3 d, p-hCG mea­
sured, and new media added. There is a continual increase in the [B-hCG), 
this despite the fact that histologic analysis at day 26 reveals that the epider­
mis has matured into a stratum corneum that contains few to no nuclei. 
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